Pain treatment with opioids: Achieving the minimal effective and the minimal interacting dose

Clinical Drug Investigation

Volumn 29, Issue SUPPL. 1, 2009, Pages 3-16

  Geppetti, Pierangelo ^a   Benemei, Silvia ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; ANTIOBESITY AGENT; ANTIPARKINSON AGENT; ANTIRETROVIRUS AGENT; BENZODIAZEPINE; BUPRENORPHINE; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL MUSCLE RELAXANT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENTANYL; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROMORPHONE; HYPNOTIC AGENT; METHADONE; MICONAZOLE; MORPHINE; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; OXYCODONE; PERGOLIDE; ROPINIROLE; SEDATIVE AGENT; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ANALGESIC ACTIVITY; BINDING AFFINITY; CANCER PAIN; CONFUSION; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSPHORIA; FOOD; FOOD DRUG INTERACTION; HALLUCINATION; HIGH RISK PATIENT; HUMAN; HYPERALGESIA; MYOCLONUS; NAUSEA AND VOMITING; NIGHTMARE; NONHUMAN; PAIN; POLYPHARMACY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; SUSTAINED RELEASE FORMULATION; URINE RETENTION; VOMITING;

ANALGESICS, OPIOID; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG UTILIZATION; HUMANS; ITALY; PAIN; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, OPIOID;

EID: 65949105476     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/0044011-200929001-00002     Document Type: Review

References (53)

1. Law PY, Wong YH, Loh HH. Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 2000; 40: 389-430
2. Waldhoer M, Bartlett SE, Whistler JL. Opioid Receptors. Annu Rev Biochem 2004; 73: 953-90
3. Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 2008; 154: 384-96
4. Machelska H, Stein C. Leukocyte-derived opioid peptides and inhibition of pain. J Neuroimmune Pharmacol 2006; 1: 90-7
5. Rittner HL, Brack A, Stein C. Pain and the immune system. Br J Anaesth 2008; 101: 40-4
6. Kondo I, Marvizon JC, Song B, et al. Inhibition by spinal muand delta-opioid agonists of afferent-evoked substance P release. J Neurosci 2005; 25: 3651-60
7. Collin E, Frechilla D, Pohl M, et al. Opioid control of the release of calcitonin gene-related peptide-like material from the rat spinal cord in vivo. Brain Res 1993; 609: 211-22
8. Sivam SP, Ho I. K. GABA in morphine analgesia and tolerance. Life Sci 1985; 37: 199-208
9. Ma J, Pan ZZ. Contribution of brainstem GABA(A) synaptic transmission to morphine analgesic tolerance. Pain 2006; 122: 163-73
10. Kieffer BL. Opioids: first lessons from knockout mice. Trends Pharmacol Sci 1999; 20: 19-26
11. Herz A. Opioid reward mechanisms: a key role in drug abuse? Can J Physiol Pharmacol 1998; 76: 252-8
12. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain 2002; 18: S3-13
13. Hoskin PJ, Hanks GW, Aherne GW, et al. The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br J Clin Pharmacol 1989; 27: 499-505
14. Hasselström J, Säwe J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet 1993; 24: 344-54
15. Andersen G, Sjøgren P, Hansen S, et al. Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain. Eur J Pain 2004; 8: 263-71
16. Sinatra R. The fentanyl HCl patient-controlled transdermal system (PCTS): an alternative to intravenous patient-controlled analgesia in the postoperative setting. Clin Pharmacokinet 2005; 44 Suppl. 1: 1-6
17. Lehmann KA, Zech D. Transdermal fentanyl: clinical pharmacology. J Pain Symptom Manage 1992; 7: S8-16
18. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Thera 1990; 47: 639-46
19. World Health Organisation. Cancer pain relief. Geneva: World Health Organisation, 1986
20. World Health Organisation. Cancer pain relief. 2nd. Geneva: World Health Organisation, 1996
21. Morphine in cancer pain: modes of administration. Expert Working Group of the European Association for Palliative Care. BMJ 1996; 312: 823-6
22. Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Brit J Cancer 2001; 84: 587-93
23. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Available from http://www.nccn.org/professionals/physician-gls/f- guidelines.asp [Accessed 2009 Mar 16]
24. Mercadante S. Opioid titration in cancer pain: a critical review. Eur J Pain 2007; 11: 823-30
25. World Health Organisation WHO's pain relief ladder. Available from http://who.int/cancer/palliative/painladder/en/ [Accessed 2009 Mar 16]
26. Joint Formulary Committee. British National Formulary. 53rd. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2007
27. De Conno F, Ripamonti C, Fagnoni, et al. The MERITO Study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during "titration phase" in patients with cancer pain. Palliat Med 2008; 22: 214-21
28. Klepstad P, Kaasa S, Jystad A, et al. Immediate- or sustainedrelease morphine for dose finding during start of morphine to cancer patients: a randomized, double-blind trial. Pain 2003; 101: 193-8
29. Smith HS. Variations in opioid responsiveness. Pain physician 2008; 11: 237-48
30. Hanks GW, Reid C. Contribution to variability in response to opioids. Support Care Cancer 2005; 13: 145-52
31. Gatti A, Reale C, Occhioni, et al. Standard therapy with opioids in chronic pain management (ORTIBER study). Clin Drug Invest 2009; 29 Suppl. 1: 17-23
32. Paice JA, Noskin GA, Vanagunas A, et al. Efficacy and safety of scheduled dosing of opioid analgesics: a quality improvement study. J Pain 2005; 6: 639-43
33. Agency for Healt Care Policy and Research (AHCPR) Pharmacological Management. Recommendations in: Management of cancer pain. Clinical Practice Guideline No. 9 U.S. Department of Health and Human Services, Public Health Service. Rockville: 1994
34. Ripamonti C, Fagnoni E, Campa T, et al. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Support Care Cancer 2006; 14: 400-7
35. Sichetti D, Fosco B, Sasso E, et al. Analisi dei consumi ospedalieri degli analgesici oppiacei. Giornale italiano di Farmacia Clinica 2006; 20: 14-20
36. De Conno F, Ripamonti C, Brunelli C. Opioid purchases and expenditure in nine western European countries: 'are we killing off morphine? ' Palliat Med 2005; 19: 179-84
37. Janssen. Important drug warning. Available from http://www.f-da.gov/ medwatch/SAFETY/2005/duragesic-ddl.pdf [Accessed 2009 Mar 16]
38. Rhodin A. The rise of opiophobia: is history a barrier to prescribing? J Pain Palliat Care Pharmacother 2006; 20: 31-2
39. Chinellato A, Terrazzani G, Walley T, et al. Opioids in Italy: isvmarketing more powerful than the law? Lancet 2003; 362: 78
40. Hamunen K, Paakkari P, Kalso E. Trends in opioid consumptionin the Nordic countries 2002-2006. Eur J Pain 2008; 15: 15
41. Garcia del Pozo J, Carvajal A, Viloria JM, et al. Trends in the consumption of opioid analgesics in Spain. Higher increases as fentanyl replaces morphine. European J Clin Pharmacol 2008; 64: 411-5
42. Bernard SA, Bruera E. Drug interactions in palliative care. J Clin Oncol 2000; 18: 1780-99
43. Crowther NR, Holbrook AM, Kenwright R and Kenwright M. Drug interactions among commonly used medications. Chart simplifies data from critical literature review. Can Fam Physician 1997; 43: 1972-81
44. Megarbane B, Gueye P, Baud F. [Interactions between benzodiazepines and opioids]. Ann Med Interne 2003; 154: S64-72
45. Quigley C, Joel S, Patel N, et al. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. Palliat Med 2003; 17: 185-90
46. Lötsch J. Morphine metabolites as novel analgesic drugs? Curr Opin Anaesthesiol 2004; 17: 449-53
47. Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I. Psychosomatics 2003; 44: 167-71
48. Ventafridda V, Ripamonti C, De Conno F, et al. Antidepressants increase bioavailability of morphine in cancer patients. Lancet 1987; 1: 1204
49. Drewe J, Ball HA, Beglinger C, et al. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Br J Clin Pharmacol 2000; 50: 237-46
50. Rogers JF, Nafziger AN, Bertino JS. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002; 113: 746-50
51. Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61: 2289-307
52. Maurer PM, Bartkowski RR. Drug interactions of clinical significance with opioid analgesics. Drug Saf 1993; 8: 30-48
53. Haddad A, Davis M, Lagman R. The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer 2007; 15: 251-7